<html><head></head><body><div id="history-main">
			
			<div class="d_block_inner">
				<div id="actual_explanation" style="display:none;"></div>
				<div id="global-ranks" class="stat-pane">
					<div class="explanation-topper">
						<div class="left-topper">
							<h1 class="post-title">Selective Beta-2 Agonists</h1>
							<h4 class="sidebar-header tax_links"><a href="https://mrcemsuccess.com/qc/5/">Pharmacology</a> / 
	<a href="https://mrcemsuccess.com/qc/respiratory-5/">Respiratory</a></h4>
						</div>
						<div class="right-topper" id="right-info">
							<h4 class="sidebar-header" id="page-numbers">Last Updated: 28th March 2019</h4>
							<button class="simplefavorite-button" data-postid="102299" data-siteid="1" data-groupid="1" data-favoritecount="431" style=""><i class="far fa-bookmark"> </i></button>						</div>
					</div>					<div id="ex-content" class="explanation-container"><p>Selective beta-2 agonists act directly on beta-2 receptors, causing smooth muscle relaxation and dilation of the airways.</p>
<h4>Indications</h4>
<p>Mild to moderate symptoms of asthma respond rapidly to the inhalation of a selective short-acting beta2 agonist such as salbutamol or terbutaline sulfate. Short-acting beta-2 agonists have a rapid onset of action (15 minutes) and their effects last for up to 4 hours.&nbsp;Salbutamol or terbutaline sulfate can be given intravenously for severe or life-threatening acute asthma; patients should be carefully monitored and the dose adjusted according to response and heart rate.</p>
<p>Short acting beta-2 agonists are used for immediate relief of asthma symptoms, while some long-acting beta-2 agonists (e.g. salmeterol) are added to an inhaled corticosteroid in patients requiring prophylactic treatment.</p>
<h4>Cautions</h4>
<p>Beta-2 agonists should be used with caution in people with:</p>
<ul>
<li><strong>Cardiovascular disease</strong> including arrhythmias and hypertension (beta-2 agonists may cause an increased risk of arrhythmias and significant changes to blood pressure and heart rate)</li>
<li><strong>Diabetes</strong> (risk of hyperglycaemia and ketoacidosis, especially with intravenous use)</li>
<li><strong>Hyperthyroidism</strong> (beta-2 agonists may stimulate thyroid activity)</li>
<li><strong>Hypokalaemia</strong> (potentially serious hypokalaemia may result from beta-2&nbsp;agonist therapy; this effect may be potentiated in severe asthma by&nbsp;concomitant treatment with theophylline, corticosteroids, diuretics and by hypoxia)</li>
<li><strong>Susceptibility to QT-interval prolongation</strong></li>
<li><strong>Convulsive disorders</strong></li>
</ul>
<h4>Interactions</h4>
<p>Hypokalaemia may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, and diuretics. This in turn may predispose to toxicity in patients taking digoxin.</p>
<h4>Side Effects</h4>
<p>Side effects are usually dose related and include:</p>
<ul>
<li class="level2">Fine tremor â€” occurs particularly in the hands and is usually worse in the first few days of treatment.</li>
<li class="level2">Palpitations and tachycardia</li>
<li class="level2">Headache</li>
<li class="level2">Seizure</li>
<li class="level2">Anxiety</li>
<li class="level2">Hypokalaemia</li>
<li class="level2">Cardiac arrhythmia and paradoxical bronchospasm (rare)</li>
<li class="level2">Acute angle-closure glaucoma</li>
<li class="level2">QT-interval prolongation</li>
</ul>
</div>
				
						
				
				</div>	
				
			
	
			</div>
			<div id="scrollup" class="active textbook"><i class="fa fa-chevron-up"></i></div>
		</div></body></html>